Thursday, March 26, 2009

Patient Without Cure? No more . OPMoney is where MY Word Processor is!

BETHESDA, Md., March 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the Future Leaders in the Biotech Industry conference at the Millennium Broadway Hotel & Conference Center in New York City on Thursday, April 2, 2009. A simultaneous webcast of the presentation will be available on the company's website at www.micromet-inc.com

Forum: Future Leaders in the Biotech Industry
Date: Thursday, April 2, 2009
Time: 1:30 to 1:55 pm U.S. Eastern Time
Place: The Millennium Broadway Hotel & Conference Center
New York City, New York
Webcast: www.micromet-inc.com

About Micromet


Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 cli
'/>"/>

No comments: